

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to §240.14a-12

Fibrocell Science, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
- (1) Title of each class of securities to which transaction applies: _____
- (2) Aggregate number of securities to which transaction applies: _____
- (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): _____
- (4) Proposed maximum aggregate value of transaction: _____
- (5) Total fee paid: _____
- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
- (1) Amount Previously Paid: _____
- (2) Form, Schedule or Registration Statement No.: _____
- (3) Filing Party: _____
- (4) Date Filed: _____


***** Exercise Your Right to Vote *****
Important Notice Regarding the Availability of Proxy Materials for the
Stockholder Meeting to Be Held on June 12, 2019

FIBROCELL SCIENCE, INC.

FIBROCELL SCIENCE, INC.
 ATTN: CORPORATE SECRETARY
 405 ENGLEVIEW BOULEVARD
 EXTON, PA 19341

Investor Address Line 1
 Investor Address Line 2
 Investor Address Line 3
 Investor Address Line 4
 Investor Address Line 5
 John Sample
 1234 ANYWHERE STREET
 ANY CITY, ON A1A 1A1

1 OF 2
 1 2



Meeting Information

Meeting Type: Annual Meeting
For holders as of: April 15, 2019
Date: June 12, 2019 **Time:** 8:30 AM EDT
Location: Fibrocell Corporate Headquarters
 405 Engleview Boulevard
 Exton, PA 19341

B
A
R
C
O
D
E

You are receiving this communication because you hold shares in the above named company.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

Broadridge Internal Use Only
 Job #
 Envelope #
 Sequence #
 # of # Sequence #

0000422091_1 R1.0.1.18

— **Before You Vote** —
 How to Access the Proxy Materials

Proxy Materials Available to VIEW or RECEIVE:
 1. 2018 Annual Report on Form 10K 2. Notice & Proxy for 2019 Annual Meeting of Stockholders

How to View Online:
 Have the information that is printed in the box marked by the arrow → [XXXX XXXX XXXX XXXX] (located on the following page) and visit: www.proxyvote.com.

How to Request and Receive a PAPER or E-MAIL Copy:
 If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

1) BY INTERNET: www.proxyvote.com
 2) BY TELEPHONE: 1-800-579-1639
 3) BY E-MAIL*: sendmaterial@proxyvote.com

* If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow → [XXXX XXXX XXXX XXXX] (located on the following page) in the subject line.

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before May 29, 2019 to facilitate timely delivery.

— **How To Vote** —
 Please Choose One of the Following Voting Methods

Vote In Person: Many stockholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

Vote By Internet: To vote now by Internet, go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow → [XXXX XXXX XXXX XXXX] available and follow the instructions.

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

Internal Use Only

0000422091_2 R1.0.1.18

[Table of Contents](#)

Voting items

The Board of Directors recommends you vote FOR ALL the following nominees:

1. Election of Directors

Nominees

01 Marc Mazur 02 Christine St.Clare 03 Douglas J. Swirsky



The Board of Directors recommends you vote FOR the following proposals:

- 2. To approve the Fibrocell Science, Inc. 2019 Equity Incentive Plan.
- 3. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent public registered accounting firm for 2019.
- 4. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.

The Board of Directors recommends you vote 1 YEAR on the following proposal:

- 5. To recommend, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of the Company's named executive officers.

NOTE: In their discretion, the proxy holders are authorized to vote upon such other matters as may properly come before the Annual Meeting or any adjournment or postponement thereof.



Broadridge Internal Use Only
xxxxxxxxxx
xxxxxxxxxx
Cusip
Job #
Envelope #
Sequence #
of # Sequence

0000422091_3 R1.0.1.18